IMPACT OF CLINICAL PARAMETERS AND SYSTEMIC INFLAMMATORY STATUS ON EPIDERMAL GROWTH FACTOR RECEPTOR-MUTANT NON-SMALL CELL LUNG CANCER PATIENTS READMINISTRATION WITH EPIDERMAL GROWTH FACTOR
Tìm thấy 10,000 tài liệu liên quan tới tiêu đề "Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-m...":
Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) readministration to lung cancer patients is common owing to the few options available. Impact of clinical factors on prognosis of EGFR-mutant non-small cell lung cancer (NSCLC) patients receiving EGFR-TKI readministration after[r]
Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: A
Central nervous system (CNS) brain metastasis of advanced non-small cell lung cancer (NSCLC) patients confers a worse quality of life and prognosis. The efficacy comparison of two first-generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib as first-line treatment for C[r]
BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: A first-inhuman phase-I study
BK-UM (CRM197) is a mutant form of diphtheria toxin and a specific inhibitor of heparin-binding epidermal growth factor-like growth factor (HB-EGF). We assessed the safety, pharmacokinetics, recommended dose, and efficacy of BK-UM in patients with recurrent ovarian cancer (OC) or peritoneal cancer ([r]
PREDICTION OF RESPONSE TO ANTI-EGFR ANTIBODY-BASED THERAPIES BY MULTIGENE SEQUENCING IN COLORECTAL CANCER PATIENTS
The anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (moAbs) cetuximab or panitumumab are administered to colorectal cancer (CRC) patients who harbor wild-type RAS proto-oncogenes.
11 Đọc thêm
EXPANSIVE HEMATOMA IN DELAYED CEREBRAL RADIATION NECROSIS IN PATIENTS TREATED WITH T-DM1: A REPORT OF TWO CASES
Multiple new targeted agents have been developed for patients with human epidermal growth factor receptor type 2 (HER2) – positive breast cancer. Patients with HER2– positive breast cancer will develop brain metastases with greater incidence than patients with non-HER2 cancers, and many of them will[r]
TÀI LIỆU BÁO CÁO KHOA HỌC EPIDERMAL GROWTH FACTOR RECEPTOR IN RELATION TO TUMOR DEVELOPMENT EGFR GENE AND CANCER PPT
below) leads to the formation of homodimers andheterodimers. This process is mediated by rotation ofdomains I and II, leading to promotion from a teth-ered configuration to an extended configuration(Fig. 1B) [2]. This exposes the dimerization domain.ERBB2 does not have corresponding liga[r]
8 Đọc thêm
COST-EFFECTIVENESS AND RESOURCE USE OF IMPLEMENTING MRI-GUIDED NACT IN ER-POSITIVE/HER2-NEGATIVE BREAST CANCERS IN THE NETHERLANDS
Response-guided neoadjuvant chemotherapy (RG-NACT) with magnetic resonance imaging (MRI) is effective in treating oestrogen receptor positive/human epidermal growth factor receptor-2 negative (ER-positive/HER2-negative) breast cancer.
17 Đọc thêm
DEVELOPMENT OF A TEST THAT MEASURES REAL-TIME HER2 SIGNALING FUNCTION IN LIVE BREAST CANCER CELL LINES AND PRIMARY CELLS
Approximately 18–20% of all human breast cancers have overexpressed human epidermal growth factor receptor 2 (HER2). Standard clinical practice is to treat only overexpressed HER2 (HER2+) cancers with targeted anti-HER2 therapies. However, recent analyses of clinical trial data have found evidence t[r]
PTEN MRNA EXPRESSION IS LESS PRONOUNCED IN LEFT- THAN RIGHT-SIDED COLON CANCER: A RETROSPECTIVE OBSERVATIONAL STUDY
Several recent studies have reported that patients with metastatic colorectal cancer (CRC) whose primary tumor is located in left side of the colon have more favorable responses to anti-epidermal growth factor receptor (EGFR) antibody therapy than those with right-sided tumors.
Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptortyrosine kinase inhibitors for non-small cell lung cancer
While epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) exert a breakthrough effect, the incidence of skin disorders as a side effect has significantly reduced patients’ quality of life.
NEW ANTI-CANCER CHEMICALS ERTREDIN AND ITS DERIVATIVES, REGULATE OXIDATIVE PHOSPHORYLATION AND GLYCOLYSIS AND SUPPRESS SPHERE FORMATION IN VITRO AND TUMOR GROWTH IN EGFRVIII-TRANSFORMED
EGFRvIII is a mutant form of the epidermal growth factor receptor gene (EGFR) that lacks exons 2–7. The resulting protein does not bind to ligands and is constitutively activated. The expression of EGFRvIII is likely confined to various types of cancer, particularly glioblastomas.
15 Đọc thêm
POSITIVE STUDY: PHYSICAL EXERCISE PROGRAM IN NON-OPERABLE LUNG CANCER PATIENTS UNDERGOING PALLIATIVE TREATMENT
Patients with advanced stage non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) often experience multidimensional impairments, affecting quality of life during their course of disease. In lung cancer patients with operable disease, several studies have shown that exercise has a posi[r]
AT-101 ENHANCES GEFITINIB SENSITIVITY IN NON-SMALL CELL LUNG CANCER WITH EGFR T790M MUTATIONS
Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have become the standard care of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), development of acquired resistance is inevitable.
8 Đọc thêm
TUMOR ENDOTHELIAL ELTD1 AS A PREDICTIVE MARKER FOR TREATMENT OF RENAL CANCER PATIENTS WITH SUNITINIB
Patients with metastatic renal cell cancer (mRCC) are commonly treated with the tyrosine kinase inhibitor sunitinib, which blocks signalling from vascular endothelial growth factor (VEGF) - and platelet-derived growth factor-receptors, inhibiting development of new blood vessels.
8 Đọc thêm
UPAR ENHANCES MALIGNANT POTENTIAL OF TRIPLE-NEGATIVE BREAST CANCER BY DIRECTLY INTERACTING WITH UPA AND IGF1R
Due to lack of a targeted therapy for the triple-negative breast cancer (TNBC) patients, it is important to explore this aggressive breast cancer type in more detail and to establish novel therapeutic approaches. TNBC is defined negative for the protein expression of oestrogen receptor (ER), progest[r]
12 Đọc thêm
CLINICAL MANAGEMENT AND OUTCOME OF PATIENTS WITH ADVANCED NSCLC CARRYING EGFR MUTATIONS IN SPAIN
Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several clinical trials, data from clinical practice is lacking and the optimal EGFR TKI to be used remains unclear.
BÁO CÁO KHOA HỌC: CALMODULIN-MEDIATED REGULATION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR DOC
inhibiting SERCA with thapsigargin also stimulatesEGFR phosphorylation and downstream mitogen-activated protein kinase signalling in intestinal epithe-lial cells [115]. This suggests that a Ca2+-dependentmechanism could be involved. Further confirmationwas obtained during EGFR transacti[r]
16 Đọc thêm
OPTIMAL REGIMEN OF TRASTUZUMAB IN COMBINATION WITH OXALIPLATIN/ CAPECITABINE IN FIRST-LINE TREATMENT OF HER2-POSITIVE ADVANCED GASTRIC CANCER (CGOG1001): A MULTICENTER, PHASE II TRIAL
The ToGA study showed that trastuzumab plus chemotherapy prolonged median survival in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. Among chemotherapy options, oxaliplatin might be as effective as cisplatin but has shown to be more tolerable.
BÁO CÁO KHOA HỌC: MEMBRANE DISTRIBUTION OF EPIDERMAL GROWTH FACTOR RECEPTORS IN CELLS EXPRESSING DIFFERENT GANGLIOSIDES DOC
tion with cold Triton X-100 in order to investigate theirassociation with GEM. The results revealed that themajority of plasma membrane GD3 reside in GEM.Confirming previous work, we found that after extractionwith nonionic detergent, GD3 was associated with lowFig. 5. [r]
10 Đọc thêm
CUMULATIVE SMOKING DOSE AFFECTS THE CLINICAL OUTCOMES OF EGFR-MUTATED LUNG ADENOCARCINOMA PATIENTS TREATED WITH EGFR-TKIS: A RETROSPECTIVE STUDY
Although lung adenocarcinoma with activating epidermal growth factor receptor (EGFR) mutations is common in never smokers, one-third of the patients are ever-smokers. We aimed to investigate the effect of cumulative smoking dose(CSD) on clinical outcomes, including progression-free survival (PFS) an[r]